1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,094 | 0,156 | 13:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Cantargia Announces IL-17 as Second Target for Bispecific CAN14 Antibody | 215 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 9, 2026 / Cantargia AB (publ) (STO:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced IL-17... ► Artikel lesen | |
| 05.11. | Cantargia to host Q3 2026 Interim Results Conference Call | 266 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 5, 2026 / Cantargia AB (publ) "Cantargia" (STO:CANTA) will publish its interim report for January - September 2026 on Wednesday, November 25, 2026, at 07:00 a.m.... ► Artikel lesen | |
| 04.11. | Cantargia Presents Promising Early Results with Nadunolimab in MDS and AML Ahead of ASH 2026 | 353 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 4, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced... ► Artikel lesen | |
| 29.10. | Cantargia Presents Nomination Committee Ahead of 2027 AGM | 328 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 29, 2026 / Cantargia AB (publ)(STO:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today provided notification... ► Artikel lesen | |
| 27.10. | Cantargia to Present at the Stifel 2026 Healthcare Conference | 329 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 27, 2026 / Cantargia AB (publ) (NASDAQ Stockholm:CANTA) today announced that representatives from the company's executive management will hold a company presentation... ► Artikel lesen | |
| 26.10. | Cantargia Appoints Dr. Monic Stuart as Chief Medical Officer | 311 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 26, 2026 / Cantargia AB (publ)(STO:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced the appointment... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 26.10. | Cantargia AB: Cantargia appoints Dr. Monic Stuart as Chief Medical Officer | 148 | GlobeNewswire (Europe) | Cantargia AB (publ) (Nasdaq Stockholm: CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced the appointment of Monic Stuart, MD, PhD... ► Artikel lesen | |
| 30.09. | Cantargia Highlights Preclinical Data at AACR Supporting Nadunolimab in Combination with RAS Inhibition in PDAC | 406 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 30, 2026 / Cantargia AB (publ) (STO:CANTA) today announced the presentation of a poster on nadunolimab in combination with RAS inhibition in pancreatic ductal... ► Artikel lesen | |
| 14.09. | Cantargia auf der H.C. Wainwright Konferenz: IL1RAP-Daten im Fokus | 5 | Investing.com Deutsch | ||
| 28.08. | Cantargia to Participate in Upcoming Investor Conferences | 514 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 28, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that management will participate in the following investor conferences during September 2026.H.C.... ► Artikel lesen | |
| 19.08. | Cantargia Q2 2026 slides: cash runway extends, MDS remissions shine | 1 | Investing.com | ||
| 19.08. | Cantargia Publishes Half-Year Report 2026 | 545 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 19, 2026 / Cantargia AB (publ) (STO:CANTA) today published its interim report for the second quarter and first six months of 2026."Over the next nine to twelve months... ► Artikel lesen | |
| 19.08. | Cantargia AB: Cantargia publishes Half-Year Report 2026 | 274 | GlobeNewswire (Europe) | Cantargia AB (publ) (Nasdaq Stockholm: CANTA) today published its interim report for the second quarter and first six months of 2026.
"Over the next nine to twelve months, we will lay the groundwork... ► Artikel lesen | |
| 04.08. | Cantargia to Host Q2 2026 Interim Results Conference Call | 385 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 4, 2026 / Cantargia AB (publ), "Cantargia" (STO:CANTA) will publish its interim report for January - June 2026 on Wednesday, August 19, 2026, at 07:00 a.m. CEST.Interested... ► Artikel lesen | |
| 31.07. | Cantargia Announces Changes in Number of Shares and Votes | 614 | ACCESS Newswire | LUND, SE / ACCESS Newswire / July 31, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that the number of shares and votes in Cantargia has changed due to the recently... ► Artikel lesen | |
| 26.06. | Cantargia Announces Publication of Data Supporting IL1RAP as a Therapeutic Target and Predictive Biomarker in PDAC | 479 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 26, 2026 / Cantargia AB (publ) (STO:CANTA) today announced the publication of preclinical and clinical findings from the nadunolimab trial CANFOUR in the scientific... ► Artikel lesen | |
| 23.06. | Cantargia AB: Cantargia announces outcome in rights issue and resolves on a directed issue of warrants to Fenja Capital | 333 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE... ► Artikel lesen | |
| 11.06. | Cantargia and H.C. Wainwright to Host KOL Call on The Case for Nadunolimab in PDAC | 366 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 11, 2026 / Cantargia AB (Publ) (STO:CANTA) today announced a KOL Call to be hosted in collaboration with H.C. Wainwright with leading subject matter experts Drs. Peter... ► Artikel lesen | |
| 10.06. | Cantargia Announces Start of New Investigator-Initiated Lung Cancer Prevention Study | 499 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 10, 2026 / Cantargia AB (Publ) (STO:CANTA) today reported that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current... ► Artikel lesen | |
| 05.06. | Cantargia AB: Cantargia publishes Information Document regarding Rights Issue of Shares | 368 | GlobeNewswire (Europe) | Cantargia AB (publ) ("Cantargia" or the "Company") publishes an information document (the "Information Document") relating to the rights issue of shares of approximately SEK 124 million before deduction... ► Artikel lesen |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,70 | +0,06 % | BioNTech zahlt 205 Millionen Dollar für schnellere FDA-Prüfung | Für 205 Millionen US-Dollar sichert sich BioNTech die Möglichkeit, die Prüfung eines künftigen Krebsmedikaments durch die US-Arzneimittelbehörde FDA zu beschleunigen. Das Mainzer Biotechnologieunternehmen... ► Artikel lesen | |
| EVOTEC | 2,966 | -5,06 % | Aktien KW 45 Blaue Welle schockt KI. Kurz. Jetzt der Weg frei? News. Rheinmetall. RENK. Mutares. ABO Energy. AMG Critical Materials. Evotec. KONTRON. UMT. Deutz. Nordex. Schäffler. WAYDEAR. Elring-Klinger. Hensoldt. SGL Carbon. Krones. aap Implantate. STE | Aktienmärkte haben eine Entscheidung, das mögen die Aktien. Klarheit - blaue Welle bremst den alten Mann ein. Möglicherweise werden KI-Investitionen einen gewissen Gegenwind erfahren, möglicherweise... ► Artikel lesen | |
| QIAGEN | 45,300 | +0,13 % | QIAGEN N.V.: QIAGEN-Aktionäre stimmen der Berufung von Jonathan M. Pratt in die Geschäftsführung mit überwältigender Mehrheit zu | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass die Aktionärinnen und Aktionäre auf einer Außerordentlichen Hauptversammlung der Berufung von Jonathan M. Pratt... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 862,00 | -0,59 % | Regeneron-Aktie: Erneute Aufwärtsbewegung nach Konsolidierung | Nach den jüngsten Quartalsergebnissen erreichte Regeneron ein neues Jahreshoch, bevor eine Konsolidierung einsetzte. Die anschließende Kurserholung hat ein höheres Tief hinterlassen, während das bisherige... ► Artikel lesen | |
| BRAIN BIOTECH | 2,530 | -2,32 % | BRAIN Biotech und Syngenta kooperieren bei biologischem Pflanzenschutz | BRAIN Biotech hat mit dem Agrarkonzern Syngenta eine strategische Zusammenarbeit zur Entwicklung biologischer Pflanzenschutzlösungen vereinbart. Im Mittelpunkt steht der Einsatz synthetischer Biologie... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,950 | +4,17 % | Milliardenchance Herztherapie: Cardiol Therapeutics, Kiniksa und Novo Nordisk | Erstellt und veröffentlicht im Auftrag von Cardiol Therapeutics Die Behandlung von entzündlichen Herzerkrankungen entwickelt sich aktuell zu einem der lukrativsten Segmente der Pharmabranche. Das bislang... ► Artikel lesen | |
| CSL | 124,34 | +0,37 % | CSL LIMITED: Update - Notification of buy-back - CSL | ||
| BURCON NUTRASCIENCE | 0,520 | -9,57 % | Burcon NutraScience Corporation: Burcon Announces Fiscal Year 2027 Second Quarter Conference Call and Presentation to be Held on November 16, 2026 | Vancouver, British Columbia--(Newsfile Corp. - November 12, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| MANNKIND | 3,716 | -0,72 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 5,500 | -2,65 % | Ocular Therapeutix outlines Q4 2026 AXPAXLI NDA plan with $530.6M cash runway into 2028 | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,446 | -0,33 % | Oxford Nanopore Tech - Share Incentive Plan - Director/PDMR Shareholding | ||
| ADAPTIMMUNE THERAPEUTICS | 0,025 | -100,00 % | Merck And ADAP Crisis Task Force Reach Agreement To Expand IDVYNSO Access | ||
| CODEXIS | 1,034 | +0,39 % | Stifel reiterates Codexis stock rating on pharma demand strength | ||
| CORMEDIX | 4,215 | -0,19 % | CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates | ||
| TELO GENOMICS | 0,024 | +2,13 % | Telo Genomics Corp (2): Telo Genomics closes $250,000 term loan with BrightArc |
CANTARGIA AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,095 Euro und damit -4,43 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.